Trials / Unknown
UnknownNCT05380024
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ensartinib | Ensartinib 225mg QD 8 weeks |
Timeline
- Start date
- 2022-08-17
- Primary completion
- 2023-12-30
- Completion
- 2024-06-30
- First posted
- 2022-05-18
- Last updated
- 2022-08-18
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05380024. Inclusion in this directory is not an endorsement.